explore -WSS

explore

author：knowledge 2025-09-27 12:48:11 - browse：1771

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Harvard's David Sinclair gets blowback over aging

focus

WSS

Immune cells and nerve overgrowth may explain recurring UTI pain

Men with early prostate cancer can safely opt out of treatment

Pregnant women don't need prenatal multivitamins, study concludes

Clinic falsely told dozens they had Alzheimer's, suits say

Families look for replacement for GSK asthma drug Flovent

New requirements coming in 2024 for Americans traveling to Europe

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Ozempic has benefits for kidney disease as well as diabetes

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Families look for replacement for GSK asthma drug Flovent

Apple is now the first public company to be valued at $3 trillion

Men with early prostate cancer can safely opt out of treatment

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

After affirmative action ruling, medical educators look to 'holistic review'

Why Talkspace is targeting Medicare, a tricky market

hotspot

4 missing after record

Harvard's David Sinclair gets blowback over aging

Readout Newsletter: BridgeBio, Akero, and human embryo models

4 missing after record

The public health thinking behind the CDC’s new Covid guidance

Sophia Smith scores twice for US in in 3

entertainment

focus

focus

leisure time